Cagrilintide vs Retatrutide: Comparing the Indexed Record
Cagrilintide and Retatrutide are routinely cross-referenced by researchers scoping a literature review. The two records are not equivalent.
Side-by-side research profile
| Parameter | Cagrilintide | Retatrutide |
|---|---|---|
| PubMed indexed records | 98 | 180 |
| Registered studies (ClinicalTrials.gov) | 44 | 34 |
| Literature depth | Moderate | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Compound profiles
Cagrilintide in the indexed record
Cagrilintide returns 98 indexed records on PubMed, a moderate record, alongside 44 registered studies on ClinicalTrials.gov.
Publications carrying this compound include BMJ, J Med Chem, Lancet, spanning 2021–2024.
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis — BMJ, 2024. PMID: 38286487
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial — Lancet, 2023. PMID: 37364590
- Development of Cagrilintide, a Long-Acting Amylin Analogue — J Med Chem, 2021. PMID: 34288673
Retatrutide in the indexed record
The literature on Retatrutide is a moderate body of work: 180 PubMed-indexed records, alongside 34 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Nat Med.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Nat Med, 2024. PMID: 38858523
How the literature differs
The indexed record is not symmetrical between these two compounds. Retatrutide carries 82 more indexed records than Cagrilintide, which means published methodology, characterisation data and replication attempts are more readily located for Retatrutide. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (44 vs 34) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Classification and why it matters
Cagrilintide and Retatrutide sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Cagrilintide describes conditions validated for Cagrilintide: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Retatrutide without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Storage and stability
Lyophilised peptide is the stable form. Held sealed at -20°C and shielded from light, it tolerates long storage; once reconstituted that tolerance drops sharply and the working solution is treated as short-lived.
Each freeze-thaw cycle costs integrity, which is why reconstituted material is normally split into single-use aliquots.
Selecting between them for a study design
Cagrilintide and Retatrutide are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Retatrutide) generally offers more methodological precedent.
Frequently asked questions
Which of Cagrilintide or Retatrutide has more published research?
Retatrutide, with 180 indexed PubMed records against 98.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Are Cagrilintide and Retatrutide the same compound?
No. They are structurally distinct research compounds with separate literature records — 98 indexed records for Cagrilintide and 180 for Retatrutide.
Related references
- Retatrutide — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.